Karen Miller, MD
Pulmonary Disease · Meridian, IDNPI 1629117619
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,576 of the $12,366 with a category attached, or 69.3%. Vertex accounts for 63.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $8,824 and has fallen 94.5% since, to $487 in 2025. Among pulmonary disease clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $116.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$8K
- Genentech, Inc.$3K
- AstraZeneca$486
- Insmed, Inc.$277
- AbbVie$259
- Gilead$156
- plus $644 from 16 others
Across 79 payments — averaging $15,015 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$698K
- AstraZeneca$231K
- Astrazeneca UK Limited$142K
- Genentech, Inc.$57K
- Pfizer$55K
- Vertex$2K
- plus $1K from 2 others
What the payments were for
- Consulting fees$8,57669%
- Travel & lodging$1,48812%
- Food & beverage$2,27318%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 34 | $7,884 |
| Genentech, Inc. | 3 | $2,660 |
| AstraZeneca | 5 | $486 |
| Insmed, Inc. | 8 | $277 |
| AbbVie(2 entities) | 13 | $259 |
| Gilead | 7 | $156 |
| Chiesi USA, Inc. | 5 | $84 |
| Nestle Healthcare Nutrition Inc. | 5 | $75 |
| Advanced Respiratory, Inc | 3 | $68 |
| Mylan Specialty L.p. | 3 | $61 |
| Merck | 4 | $48 |
| Digestive Care, Inc. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $40 |
| Baxter Healthcare | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Philips North America LLC | 1 | $23 |
| PARI Respiratory Equipment, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,366 in reported general payments places this provider in the 90th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 119 | $3,144,301 |
| OfevNintedanib Esylate | 56 | $720,994 |
| UptraviSelexipag | 21 | $470,453 |
| AdempasRiociguat | 22 | $310,155 |
| CreonLipase/Protease/Amylase | 37 | $217,807 |
| ZenpepLipase/Protease/Amylase | 28 | $183,318 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 180 | $150,193 |
| PertzyeLipase/Protease/Amylase | 15 | $49,815 |
| Spiriva RespimatTiotropium Bromide | 70 | $39,491 |
| Pirfenidone | 23 | $35,931 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $29,749 |
| Ambrisentan | 17 | $22,301 |
| Tadalafil | 18 | $16,850 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $13,474 |
| Spiriva HandihalerTiotropium Bromide | 19 | $12,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $7,884 | $3,144,301119 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $40 | $760,485126 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $45 | $470,45321 claims |
| AbbVieCreon | $259 | $217,80737 claims |
| Aimmune Therapeutics, Inc.Zenpep | $18 | $183,31828 claims |
| Digestive Care, Inc.Pertzye | $48 | $49,81515 claims |
| AstraZenecaSymbicort | $486 | $8,92627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Meridian
- Oleg KouskovMeridian$8K
- Matthew DivietroMeridian$4K
- Eric ScholtenMeridian$716
- Andrew RegerMeridian$677
- William BergquistMeridian$479
- William DittrichMeridian$310
- David FonsecaMeridian$287
- Olga FortenkoMeridian$190
- Brian GoltryMeridian$151
- David WylerMeridian$73
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.